Sonus Pharmaceuticals to Present at WBBA Invest Northwest(TM)
19 Marzo 2007 - 4:39PM
Business Wire
Sonus Pharmaceuticals, Inc. (NASDAQ: SNUS), an oncology drug
development company, today announced that Alan Fuhrman, Senior Vice
President and CFO, will present at the Washington Biotechnology and
Biomedical Association (WBBA) Invest Northwest conference on
Tuesday, March 20, 11:55 A.M. PT. The conference is being held in
Seattle March 20-21. The Company�s presentation will be broadcast
live at www.sonuspharma.com/events.html. An archive of the call
will be available through the same link. About Sonus
Pharmaceuticals Located near Seattle, Washington, Sonus
Pharmaceuticals, Inc. is focused on the development of cancer drugs
that are designed to provide better efficacy, safety and
tolerability, and are more convenient to use. The Company�s lead
product candidate, TOCOSOL Paclitaxel, is currently in a Phase 3
pivotal trial in metastatic breast cancer. TOCOSOL Paclitaxel may
have the ability to offer an easier to use and potentially safer
and more effective alternative paclitaxel therapy for cancer
patients. In addition to the continuing development of TOCOSOL
Paclitaxel, Sonus initiated the Phase 1 clinical program for its
second cancer drug, TOCOSOL Camptothecin, in September 2006. The
Company�s objective with TOCOSOL Camptothecin is to provide a
ready-to-use product that has enhanced efficacy and improved
tolerability compared to the commercially available camptothecin
analogs. For additional information on Sonus, including past news
releases, please visit www.sonuspharma.com. Safe Harbor Certain
statements made in this press release are forward-looking such as
those, among others, relating to the development, safety and
efficacy of therapeutic drugs and potential applications for these
products. As discussed in Sonus Pharmaceuticals' filings with the
Securities and Exchange Commission, including its Annual Report on
Form 10-K for 2006, actual results could differ materially from
those projected in the forward-looking statements as a result of
the following factors, among others:�the Company's products will
require extensive clinical testing and approval by regulatory
authorities; such approvals are lengthy and expensive and may never
occur; risks that the Company will not be able to complete the
Phase 3 clinical trial for TOCOSOL Paclitaxel; risks that clinical
studies with TOCOSOL Paclitaxel will be delayed or will not be
successful; risks that the FDA may not approve the TOCOSOL
Paclitaxel New Drug Application; risks that the Phase 1 clinical
trial for TOCOSOL Camptothecin will not be successful; risks of
successful development of therapeutic drugs; and risks that the
Company may not be successful in obtaining funding from third
parties or completing a financing necessary to support the costs
and expenses of clinical studies as well as research and
development activities. The Company undertakes no obligation to
update the forward-looking statements contained herein or to
reflect events or circumstances occurring after the date hereof.
Sonus (NASDAQ:SNUS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Sonus (NASDAQ:SNUS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Sonus Pharmaceuticals (MM) (NASDAQ): 0 recent articles
Más de Sonus Pharmaceuticals, Inc. Artículos de Noticias